Free tool
FAERS Monitor: Targretin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021056 or its brand name (Targretin, Bexarotene). Reports on generic versions are filed under their own applications.
Reports
1,325
Serious
998
75% of reports
Hospitalization
395
Death reported
250
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective113
- off label use77
- death76
- hypothyroidism75
- hypertriglyceridaemia59
- disease progression58
- fatigue50
- pruritus47
- malignant neoplasm progression43
- condition aggravated39
- nausea37
- pneumonia34
- mycosis fungoides30
- product use in unapproved indication28
- cutaneous t-cell lymphoma27
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 12 |
| 2005 | 19 |
| 2006 | 28 |
| 2007 | 27 |
| 2008 | 28 |
| 2009 | 31 |
| 2010 | 31 |
| 2011 | 33 |
| 2012 | 30 |
| 2013 | 35 |
| 2014 | 33 |
| 2015 | 70 |
| 2016 | 73 |
| 2017 | 77 |
| 2018 | 87 |
| 2019 | 104 |
| 2020 | 97 |
| 2021 | 84 |
| 2022 | 115 |
| 2023 | 86 |
| 2024 | 75 |
| 2025 | 88 |
| 2026 | 61 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,834 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| mycosis fungoidesSignal | 30 | 601.1 | 419.1 | 16,745 |
| cutaneous t-cell lymphomaSignal | 27 | 347.9 | 238.5 | 8,804 |
| hypertriglyceridaemiaSignal | 59 | 161.6 | 125.8 | 9,166 |
| hypothyroidismSignal | 75 | 37.4 | 30.0 | 2,616 |
| disease progressionSignal | 58 | 7.8 | 6.1 | 338 |
| malignant neoplasm progressionSignal | 43 | 6.7 | 5.0 | 202 |
| condition aggravatedSignal | 39 | 2.0 | 1.5 | 20 |
| pruritus | 47 | 1.9 | 1.5 | 21 |
| product use in unapproved indication | 28 | 1.8 | 1.2 | 9 |
| pneumonia | 34 | 1.7 | 1.2 | 9 |
| death | 76 | 1.4 | 1.1 | 9 |
| off label use | 77 | 1.4 | 1.1 | 9 |
| drug ineffective | 113 | 1.4 | 1.1 | 11 |
| fatigue | 50 | 1.0 | 0.8 | 0 |
| nausea | 37 | 0.7 | 0.5 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.